Close
 

Figure 4: Univariable analysis of median overall survival between the gemcitabine and docetaxel groups. (a) Time to disease progression >1 year versus <1 year. (b) Single organ involvement vs. multiple organ involvement. (c) Liver metastasis versuss without liver metastasis. (d) Gemcitabine group versus docetaxel group

Figure 4: Univariable analysis of median overall survival between the gemcitabine and docetaxel groups. (a) Time to disease progression >1 year versus <1 year. (b) Single organ involvement vs. multiple organ involvement. (c) Liver metastasis versuss without liver metastasis. (d) Gemcitabine group versus docetaxel group